Centogene NV (Centogene NV) Capex-to-Revenue : 0.00 (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Centogene NV Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Centogene NV's Capital Expenditure for the three months ended in Jun. 2023 was $0.00 Mil. Its Revenue for the three months ended in Jun. 2023 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

Centogene NV Capex-to-Revenue Historical Data

The historical data trend for Centogene NV's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centogene NV Capex-to-Revenue Chart

Centogene NV Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Capex-to-Revenue

Get a 7-Day Free Trial

0.29

0.16

0.43

0.14

0.04

Centogene NV Quarterly Data
	Dec17	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
Capex-to-Revenue	Get a 7-Day Free Trial															-	0.01	0.08	-	-

Competitive Comparison of Centogene NV's Capex-to-Revenue

For the Diagnostics & Research subindustry, Centogene NV's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Centogene NV's Capex-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Centogene NV's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Centogene NV's Capex-to-Revenue falls into.

Centogene NV Capex-to-Revenue Calculation

Centogene NV's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-2.218)	/	50.289
	=	0.04

Centogene NV's Capex-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0
	=	N/A

Centogene NV (NAS:CNTG) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Centogene NV Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Centogene NV's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Centogene NV (Centogene NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Centogene NV (NAS:CNTG) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

39K:Germany

Address

Am Strande 7, Rostock, MV, DEU, 18055

Website

https://www.centogene.com

Centogene NV is a United States-based company focused on transforming clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company operates in three segments: pharmaceutical, diagnostics, and COVID-19. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its clinical diagnostics segment provides targeted genetic sequencing and diagnostics services to patients.